Compare
Up to four compounds, side by side.
Search or pick a starting set. Differences light up so you can spot them fast.
ACE-031
1 / 4
Peptide
Myostatin Inhibitor
ACE-031Overview
Summary
Clinical-grade myostatin pathway inhibitor — terminated in muscle dystrophy trials.
Category
Myostatin Inhibitor
Mechanism
Soluble activin receptor type IIB decoy — sponges up myostatin.
Effects
Top outcomes
- Lean muscle72
Evidence
Emerging
Practical
Half-life
~10-15 days
Administration
subq
Risk
Legal status
research only
Safety
Vascular side effects (nosebleeds, gum bleeding) led to trial halts.
Try a preset